<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1729-519X</journal-id>
<journal-title><![CDATA[Revista Habanera de Ciencias Médicas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev haban cienc méd]]></abbrev-journal-title>
<issn>1729-519X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de la Habana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1729-519X2019000600873</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tomografía por emisión de positrones con 18F-fluordeoxiglucosa-tomografía computarizada en el diagnóstico del tumor primario de origen desconocido]]></article-title>
<article-title xml:lang="en"><![CDATA[Value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography &#305;n the diagnosis of carcinoma of unknown primary origin]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Espinosa]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oliva González]]></surname>
<given-names><![CDATA[Juan Perfecto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Ramírez]]></surname>
<given-names><![CDATA[Aldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González González]]></surname>
<given-names><![CDATA[Joaquín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calderón Marín]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vázquez Luna]]></surname>
<given-names><![CDATA[Frank]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quesada Cepero]]></surname>
<given-names><![CDATA[Waldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Oncología y Radiobiología  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Oncología y Radiobiología Universidad de Ciencias Médicas de La Habana ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital General Docente &#8220;Dr. Enrique Cabrera&#8221;  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>18</volume>
<numero>6</numero>
<fpage>873</fpage>
<lpage>885</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1729-519X2019000600873&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1729-519X2019000600873&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1729-519X2019000600873&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La incidencia de tumores primarios de origen desconocido en pacientes oncológicos es del 0,5 al 7 % en el momento del diagnóstico con una supervivencia a los 3 y 5 años de 11 y 6 %, respectivamente.  Objetivo: valorar la utilidad de la técnica PET/CT-FDG (Tomografía por emisión de positrones con 18F-Fluordeoxiglucosa) en el diagnóstico de tumor primario de origen desconocido (TOD).  Material y método: Se analizaron retrospectivamente los estudios PET/CT-FDG realizados en pacientes con el diagnóstico de TOD para la búsqueda de tumor primario, con estudios convencionales previos negativos, entre noviembre de 2017 y junio de 2018. El diagnóstico final se estableció mediante confirmación histológica y/o seguimiento clínico/radiológico por 8 meses.  Resultados: 42 pacientes fueron estudiados, en 19 estudios PET/CT se evidenciaron focos de captación sugestivos de tumor primario, de los cuales 9 se confirmaron histológicamente como verdaderos positivos y sólo 1 correspondió a un falso positivo. De los 23 pacientes con PET/CT negativos para tumor primario, todos continuaron con diagnóstico de TOD a pesar de las múltiples pruebas diagnósticas.  Conclusiones: La técnica PET/CT permitió identificar el 45,2 % de los tumores primarios en la muestra de pacientes, lo que la convierte en una herramienta útil para el diagnóstico en pacientes con metástasis de origen desconocido. Se considera que el PET/CT-FDG debe ser incluido de manera precoz en los algoritmos diagnósticos en Cuba, permitiendo orientar la realización de pruebas complementarias subsiguientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: The incidence of carcinoma of unknown primary origin in oncologic patients is from 0,5 % to 7 % at the time of diagnosis with an overall 3-year and 5-year survival of 11 % and 6%, respectively.  Objective: To assess the effectiveness of 18 F-FDG-PET/CT (18F-fluorodeoxyglucose pos&#305;tron em&#305;ss&#305;on tomography) in the diagnosis of carcinoma of unknown primary origin (CUP).  Material and Methods: F-FDG-PET/CT studies were conducted in patients with CUP in the search for primary tumor with negative previous conventional studies carried out from November, 2017 to June 2018. The final diagnosis was established by histological confirmation and/or clinical/radiological follow-up during 8 months.  Results: A total of 44 patients were studied. There were evidences of suggestive CUP in 19 patients; 9 of them were histologically confirmed as true-positive and only 1 was a false-positive. Of the 23 patients with negative F-FDG-PET/CT studies for primary tumor, all of them continued with the diagnosis of CUP in spite of multiples diagnostic tests. Conclusions: The FDG-PET/CT technique allowed to identify 45,2 % of the primary tumors in this study, which demonstrates that it is very useful tool for the diagnosis of metastases of unknown origin. It is considered that F-FDG-PET/CT studies should be included earlier in the diagnostic algorithms in Cuba, which will allow to indicate subsequent complementary tests.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tumor de origen desconocido]]></kwd>
<kwd lng="es"><![CDATA[TOD]]></kwd>
<kwd lng="es"><![CDATA[PET/CT]]></kwd>
<kwd lng="es"><![CDATA[PET-FDG]]></kwd>
<kwd lng="es"><![CDATA[Metástasis sin primario conocido]]></kwd>
<kwd lng="en"><![CDATA[Tumor of unknown origin]]></kwd>
<kwd lng="en"><![CDATA[CUP]]></kwd>
<kwd lng="en"><![CDATA[PET/CT]]></kwd>
<kwd lng="en"><![CDATA[F-FDG-PET/CT]]></kwd>
<kwd lng="en"><![CDATA[metastases from unknown primary tumor]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallegos Hernández]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metástasis ganglionares cervicales de carcinoma epidermoide con tumor primario desconocido. Abordaje diagnóstico-terapéutico actual]]></article-title>
<source><![CDATA[An Orl Mex]]></source>
<year>2016</year>
<volume>61</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-65</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pavlidis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Briasoulis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hainsworth]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Greco]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic and therapeutic management of cancer of an unknown primary]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2003</year>
<volume>39</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1990-2005</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piccioli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maccauro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Spinelli]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metástasis óseas de origen desconocido: epidemiología y principio de manejo]]></article-title>
<source><![CDATA[J. Orthop Traumatol]]></source>
<year>2015</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>81-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>NCCN (Internet) National Comprehensive Cancer Network guideline</collab>
<source><![CDATA[3025 Chemical Road, Suite 100. NCCN Health Information Technologic Licensees. Occult primary. Cancer unknown primary]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Roh]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of 18F FDG PET/CT with contrast-enhanced CT or CT/MR Imaging-prospective study]]></article-title>
<source><![CDATA[Radiology]]></source>
<year>2015</year>
<volume>274</volume>
<page-range>764-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Budak]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Yanarates]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of 18F-FDG PET/CT in the detection of primary malignancy in patients with bone metastases of onknown origin]]></article-title>
<source><![CDATA[Rev Esp Med Nucl Imagen Mol]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aplicaciones del PET/CT en oncología]]></article-title>
<source><![CDATA[Revista Nucleus]]></source>
<year>2017</year>
<volume>62</volume>
<page-range>10-3</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[R. Sopena]]></surname>
<given-names><![CDATA[Martínez C]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual PET-TAC para residentes. Costa del Sol, 3-28033]]></source>
<year>2017</year>
<volume>9</volume>
<publisher-loc><![CDATA[Madrid, España ]]></publisher-loc>
<publisher-name><![CDATA[GE healthcare]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivas Arroyo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiofármacos utilizados en la tomografía por emisión de positrones: presente y perspectivas de futuro.]]></article-title>
<source><![CDATA[Radiología]]></source>
<year>2016</year>
<volume>58</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>468-80</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sven]]></surname>
<given-names><![CDATA[N. Reske]]></given-names>
</name>
<name>
<surname><![CDATA[Kotzerke]]></surname>
<given-names><![CDATA[Jörg]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III"]]></article-title>
<source><![CDATA[Eur J Nucl Med]]></source>
<year>2001</year>
<volume>28</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1707-23</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Martino]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nowak]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopìc and histopathologic findings]]></article-title>
<source><![CDATA[Arch Otolaryngol Head and Neck]]></source>
<year>2000</year>
<volume>126</volume>
<page-range>1457-61</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: A meta-analysis]]></article-title>
<source><![CDATA[Surgical Oncology]]></source>
<year>2013</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>190-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elboga]]></surname>
<given-names><![CDATA[Umut]]></given-names>
</name>
<name>
<surname><![CDATA[Kervancio&#287;lu]]></surname>
<given-names><![CDATA[Selim]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of F-18 fluorodeoxyglucose pos&#305;tron em&#305;ss&#305;on tomography/computed &#305;n carc&#305;noma of unknown primary]]></article-title>
<source><![CDATA[Int J Clin Exp Pathol]]></source>
<year>2014</year>
<volume>7</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>8941-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hulse]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sykes]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Carrington]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Julyan]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Homer]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Should FDG-PET scanning be routinely used for patients with an unknown head and neck squamous primary?]]></article-title>
<source><![CDATA[J Laryngol Otol]]></source>
<year>2007</year>
<volume>121</volume>
<page-range>149-53</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Breuer]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Behrendt]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
<name>
<surname><![CDATA[Heinzel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mottaghy]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Palmowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Verburg]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic relevance of 18F-FDG PET/CT in carcinoma of unknown primary]]></article-title>
<source><![CDATA[Clin Nucl Med]]></source>
<year>2014</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>131-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Imperiale]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rust]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Taieb]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[18F-Fluorodihydroxyphenylalanine PET/CT in Patients with Neuroendocrine Tumors of Unknown Origin: Relation to Tumor Origin and Differentiation]]></article-title>
<source><![CDATA[Journal of Nuclear Medicine]]></source>
<year>2013</year>
<volume>55</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>367-72</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prowse]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ganeshan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Prowse]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Hanlon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis-Jones]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wieshmann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The added value of 18F-fluorodeoxyglucose positron emission tomography computed tomography in patients with neck lymph node metastases from an unknown primary malignancy]]></article-title>
<source><![CDATA[J Laryngol Otol]]></source>
<year>2013</year>
<volume>127</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>780-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary]]></article-title>
<source><![CDATA[J Med Imaging Radiat Oncol]]></source>
<year>2013</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-71</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Talabera-Rubio]]></surname>
<given-names><![CDATA[M del P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad de la tomografía por emisión de positrones con 18F-fluorodesoxiglucosatomografía computarizada en la identificación del tumor primario en pacientes con cáncer de origen desconocido]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2013</year>
<volume>140</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
